Alia Therapeutics
Company Type: Therapeutic development
Main focus: Developing CRISPR-based therapies to treat genetic diseases
Company stage: Pre-clinical
Diseases: Autosomal-dominant retinitis pigmentosa and other genetic diseases.
Genome-editing tool: CRISPR-Cas
Funding stage: Seed
Location: Trento, Trentino-Alto Adige, Italy
Website: www.aliatherapeutics.com/en/home/
Pipeline: www.aliatherapeutics.com/en/technology/
Partners:
Alia Therapeutics is a biotechnology company focused on developing CRISPR-based therapies to treat genetic diseases. Alia's research is centered on optimising gene-editing tools to improve safety, precision, and efficiency in therapeutic applications, with the goal of providing targeted treatments for a range of inherited disorders. The company’s first pipeline programme aims to develop a gene-editing treatment for autosomal-dominant retinitis pigmentosa.